Participant count type changed
Before: Estimated. After: Actual.
Enrollment · participant count changed
Before: 60 participants (planned). After: 66 participants (actual).
Recruitment status changed
Before: Recruiting. After: Active not recruiting.
Study sponsor: CytoDyn, Inc.
Primary completion is the date data collection ends for the main study measures, not when results are published.
Before: Estimated. After: Actual.
Before: 60 participants (planned). After: 66 participants (actual).
Before: Recruiting. After: Active not recruiting.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: To evaluate the efficacy of leronlimab in combination with trifluridine and tipiracil + bevacizumab in participants with CCR5+, refractory, MSS, mCRC.. After: Measure: The efficacy of leronlimab in combination with trifluridine and tipiracil + bevacizumab in participants with relapsed, refractory, MSS, mCRC..